<![CDATA[
Why Lyme Disease Testing Is So Controversial
Few areas in medicine generate as much frustration — for patients and physicians alike — as Lyme disease diagnostics. Patients suffering from debilitating symptoms are frequently told their blood tests are “negative” or “inconclusive,” leading to delayed treatment, misdiagnosis, and unnecessary suffering. Understanding why this happens requires a careful examination of how Lyme disease testing works, where it fails, and what advanced alternatives exist.
At St. George Hospital in Bad Aibling, Germany, our approach to Lyme disease diagnostics has been refined over three decades of clinical experience. Dr. Julian Douwes and our infectious disease team employ a comprehensive testing strategy that goes far beyond the limitations of standard screening to identify active infection and guide effective treatment.
The Standard Two-Tier Testing Protocol
In most countries, Lyme disease diagnosis follows a two-tier serological testing protocol recommended by the CDC and adopted by public health agencies worldwide. Understanding this system — and its limitations — is essential for any patient navigating the Lyme diagnostic landscape.
Step 1: ELISA (Enzyme-Linked Immunosorbent Assay)
The first tier is the ELISA test, a screening assay that detects antibodies (IgM and IgG) produced by the immune system in response to Borrelia burgdorferi infection. The test measures overall antibody reactivity against a preparation of Borrelia antigens.
How it works: A sample of the patient’s blood serum is placed in a well coated with Borrelia antigens. If antibodies against Borrelia are present, they bind to the antigens. An enzyme-linked secondary antibody is then added, producing a color change proportional to the amount of anti-Borrelia antibody present.
Key limitation: The ELISA is a screening test — designed to be sensitive (catching most positive cases) at the cost of specificity (accepting some false positives). However, in practice, the standard Lyme ELISA has a sensitivity of only approximately 50–70% for early Lyme disease, meaning it misses 30–50% of truly infected patients during the critical early treatment window.
Step 2: Western Blot
If the ELISA is positive or equivocal, a Western blot is performed as the confirmatory step. This test separates Borrelia proteins by molecular weight and identifies which specific antibodies the patient has produced.
How it works: Borrelia proteins are separated on a gel and transferred to a membrane. The patient’s serum is applied, and any antibodies present will bind to their target proteins, producing visible “bands” at specific positions. Each band corresponds to a specific Borrelia protein (e.g., OspC at 23 kDa, p41 flagellin at 41 kDa, p39 at 39 kDa).
CDC criteria for a positive Western blot:
- IgM: At least 2 of 3 specified bands (23, 39, 41 kDa) — valid only within the first 30 days of illness
- IgG: At least 5 of 10 specified bands
Key limitation: The requirement for multiple specific bands means that patients with genuine Borrelia infection who mount a limited antibody response — common in immunocompromised patients, those treated with early antibiotics, or those with chronic infection — may not meet the threshold for a “positive” result.
Why Standard Lyme Disease Tests Miss Infections
The two-tier system was designed for epidemiological surveillance — tracking disease prevalence in populations — not for individual clinical diagnosis. This distinction is critically important and is the source of much of the controversy surrounding Lyme testing. Several specific mechanisms explain why standard tests fail individual patients:
Delayed Antibody Response
Antibodies against Borrelia typically take 2–6 weeks to develop after infection. During this seronegative window, both ELISA and Western blot will be negative despite active infection. Patients tested early — when symptoms first appear and treatment would be most effective — are the most likely to receive false-negative results.
Antibiotic Blunting of Antibody Response
Patients who received early antibiotic treatment (even incomplete courses) may have their immune response partially suppressed, resulting in lower antibody titers that fall below test thresholds. Paradoxically, early treatment — the medically correct approach — can make subsequent serological confirmation more difficult.
Borrelia Species Diversity
Standard tests are typically calibrated to Borrelia burgdorferi sensu stricto, the predominant species in North America. In Europe, where Borrelia afzelii and Borrelia garinii are also prevalent, test sensitivity may be reduced due to antigenic differences between species. This is particularly relevant for patients who acquired their infection in Europe.
Immune Evasion by Borrelia
Borrelia is a sophisticated pathogen with multiple mechanisms for evading immune detection. The spirochete can alter its surface proteins (antigenic variation), sequester within tissues with limited immune surveillance, form biofilms, and even reside intracellularly. These evasion strategies mean that some patients with chronic infection produce antibody profiles that do not match the expected Western blot pattern.
Seronegative Lyme Disease
A subset of Lyme disease patients — estimated at 5–15% — remain persistently seronegative despite documented infection (confirmed by culture, PCR, or clinical criteria). This phenomenon is more common in immunocompromised patients and those with chronic infection, precisely the population that most needs accurate diagnostic support.
Advanced Lyme Disease Testing
Recognizing the limitations of standard serology, a growing number of specialized laboratories and Lyme-literate physicians employ advanced testing methods that can identify active infection missed by conventional approaches.
ELISpot / LTT (Lymphocyte Transformation Test)
The ELISpot (Enzyme-Linked ImmunoSpot) assay and the closely related Lymphocyte Transformation Test (LTT) measure the cellular immune response to Borrelia — a fundamentally different approach from antibody-based tests.
These tests expose the patient’s T-lymphocytes to Borrelia antigens in vitro and measure whether the immune cells mount a specific response. A positive result indicates that the immune system has been recently stimulated by Borrelia, suggesting active or recently active infection.
Advantages over serology:
- Detects cellular immunity, which may persist when antibody responses are absent
- Better at distinguishing active from past infection
- Not affected by antibiotic suppression of antibody production
- Can be positive in seronegative patients
A study published in Clinical and Vaccine Immunology demonstrated that the ELISpot assay detected Borrelia-specific T-cell responses in patients with clinical Lyme disease who were seronegative by standard testing.
CD57+ Natural Killer Cell Count
CD57+ natural killer (NK) cells are a subset of immune cells that tend to be depressed in patients with chronic Lyme disease. While not a direct test for Borrelia, the CD57+ NK cell count serves as a valuable biomarker for chronic Lyme disease activity and treatment response.
- Low CD57: Suggestive of active or chronic Borrelia infection, particularly when other testing is equivocal
- Rising CD57: Correlates with clinical improvement during treatment
- Normalized CD57: Associated with sustained remission
This marker is particularly useful for monitoring treatment progress and determining when therapy can be safely discontinued.
PCR (Polymerase Chain Reaction)
PCR testing amplifies and detects Borrelia DNA directly, providing evidence of the organism’s presence rather than the immune response to it. PCR can be performed on blood, urine, synovial fluid, or cerebrospinal fluid depending on the clinical presentation.
Advantages: Species-specific identification, not dependent on immune function
Limitations: Limited sensitivity in blood (Borrelia bacteremia is often intermittent and low-level), more useful in tissue samples and joint fluid
Culture
Borrelia culture — growing the organism from patient specimens — provides definitive proof of infection. However, Borrelia is an extremely fastidious organism that grows slowly in specialized BSK medium, making culture impractical for routine diagnosis. It remains primarily a research tool, though some specialized laboratories offer clinical Borrelia culture.
Our Diagnostic Approach at St. George Hospital
Dr. Julian Douwes has developed a comprehensive Lyme disease diagnostic protocol that integrates multiple testing modalities to maximize diagnostic accuracy:
- Detailed clinical history: Including tick exposure, symptom timeline, prior treatments, and co-infection risk assessment
- Physical examination: Focused on neurological, musculoskeletal, and dermatological findings consistent with Borrelia infection
- Standard serology: ELISA and Western blot as baseline, with full-band reporting (not limited to CDC surveillance criteria)
- Cellular immune testing: ELISpot/LTT to assess T-cell reactivity to Borrelia antigens
- CD57+ NK cell count: As a biomarker for chronic infection activity
- Co-infection panel: Comprehensive testing for Babesia, Bartonella, Ehrlichia, Anaplasma, and other relevant co-infections
- Functional assessments: Immune function panels, inflammatory markers, and organ-specific tests based on clinical presentation
This layered approach ensures that patients with genuine Borrelia infection are identified regardless of whether their antibody profile meets conventional criteria. It also identifies the co-infections and immune dysfunctions that must be addressed for treatment to succeed.
What Your Lyme Test Results Actually Mean
Positive ELISA + Positive Western Blot
Meets standard diagnostic criteria for Lyme disease. Relatively straightforward, though does not indicate whether infection is active or past.
Negative ELISA
Under two-tier protocol, a negative ELISA ends the testing process — no Western blot is performed. However, given the ELISA’s limited sensitivity (especially in early and late-stage disease), a negative ELISA does not reliably exclude Lyme disease. Further testing with more sensitive methods may be warranted based on clinical presentation.
Positive ELISA + Negative (or Indeterminate) Western Blot
Officially classified as negative under two-tier criteria. However, some patients in this category have genuine Borrelia infection with an immune response that does not meet the arbitrary band criteria. Clinical correlation and advanced testing are essential.
Positive ELISpot with Negative Serology
Suggests active Borrelia-specific cellular immune stimulation despite negative antibody testing. In the appropriate clinical context, this finding is significant and may warrant treatment.
Frequently Asked Questions About Lyme Disease Testing
Can I have Lyme disease with a negative blood test?
Yes. Standard Lyme disease testing (ELISA and Western blot) has well-documented limitations, particularly in early infection, late-stage disease, and patients who received prior antibiotic treatment. Studies suggest that 20–50% of patients with clinical Lyme disease may not meet standard serological criteria. If your symptoms are consistent with Lyme disease but standard tests are negative, advanced testing methods such as ELISpot/LTT and CD57 evaluation should be considered.
How soon after a tick bite should I get tested for Lyme disease?
Standard antibody tests are unlikely to be positive within the first 2–4 weeks after infection, as the immune system needs time to produce detectable antibodies. If you develop symptoms after a tick bite, early clinical evaluation is more important than waiting for tests to become positive. Treatment should not be delayed pending test results when clinical suspicion is high. If early testing is negative, repeat testing at 4–6 weeks is recommended.
Why do different doctors interpret my Lyme test results differently?
The interpretation of Lyme disease tests is one of the most contentious issues in infectious disease medicine. Physicians who adhere strictly to IDSA (Infectious Diseases Society of America) guidelines apply the CDC two-tier criteria as a binary diagnostic standard. Physicians with extensive experience treating chronic Lyme disease — including our team at St. George Hospital — recognize the documented limitations of this approach and interpret results within the broader context of clinical presentation, advanced testing, and treatment response.
What is the most accurate test for Lyme disease?
No single test achieves perfect accuracy for Lyme disease diagnosis. The most reliable approach is a combination of tests assessing both humoral (antibody) and cellular immune responses, along with direct detection methods where applicable. At St. George Hospital, our multi-modal diagnostic protocol — combining serology, ELISpot/LTT, CD57, co-infection panels, and comprehensive clinical evaluation — provides the most complete diagnostic picture available.
Should I get tested for co-infections along with Lyme disease?
Absolutely. Co-infections with Babesia, Bartonella, Ehrlichia, and Anaplasma are common in Lyme disease patients and significantly complicate treatment and recovery. Testing for co-infections should be considered standard practice in any thorough Lyme disease evaluation. At St. George Hospital, comprehensive co-infection screening is included in every Lyme disease workup.
Get Accurate Lyme Disease Diagnostics
If you have been told your Lyme tests are negative but continue to suffer from symptoms consistent with tick-borne illness, you may benefit from a more comprehensive diagnostic evaluation. At St. George Hospital, three decades of experience in Lyme disease diagnostics have taught us that standard tests tell only part of the story.
Contact our international patient team to arrange a thorough evaluation:
- Phone: +49 (0)8061 398-0
- Email: info@clinicum-stgeorg.de
- Online: Request a consultation
This article is for informational purposes only and does not constitute medical advice. Lyme disease diagnosis and treatment require qualified medical supervision. Individual results may vary.
]]>